$EVOK
Evoke Pharma Inc

2015 Q3 Form 10-Q Financial Statement

#000156459015010586 Filed on November 12, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2014 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $820.0K $730.0K
YoY Change 12.33% 78.05%
% of Gross Profit
Research & Development $1.838M $3.088M
YoY Change -40.49% 3822.69%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.838M $3.821M
YoY Change -51.91% 686.91%
Operating Profit -$3.821M
YoY Change 686.91%
Interest Expense $78.42K $5.906K
YoY Change 1227.87% -114.77%
% of Operating Profit
Other Income/Expense, Net -$4.181K
YoY Change 1244.37%
Pretax Income -$2.740M -$3.830M
YoY Change -28.46% 681.63%
Income Tax
% Of Pretax Income
Net Earnings -$2.735M -$3.825M
YoY Change -28.49% 687.27%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$422.2K -$633.1K
COMMON SHARES
Basic Shares Outstanding 6.100M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.74M $12.18M
YoY Change -11.82% -48.69%
Cash & Equivalents $10.74M $12.18M
Short-Term Investments
Other Short-Term Assets $940.0K $1.130M
YoY Change -16.81%
Inventory
Prepaid Expenses $1.132M
Receivables
Other Receivables
Total Short-Term Assets $11.67M $13.31M
YoY Change -12.31% -43.94%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $82.55K
YoY Change -87.89%
Total Long-Term Assets $10.00K $82.55K
YoY Change -87.89%
TOTAL ASSETS
Total Short-Term Assets $11.67M $13.31M
Total Long-Term Assets $10.00K $82.55K
Total Assets $11.68M $13.39M
YoY Change -12.78% -43.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.340M $1.050M
YoY Change 27.62% -11.02%
Accrued Expenses $670.0K $640.0K
YoY Change 4.69% 64.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0%
Total Short-Term Liabilities $2.006M $1.685M
YoY Change 19.03% -36.08%
LONG-TERM LIABILITIES
Long-Term Debt $4.369M $0.00
YoY Change -100.0%
Other Long-Term Liabilities $10.00K
YoY Change
Total Long-Term Liabilities $4.369M $10.00K
YoY Change 43587.49% -99.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.006M $1.685M
Total Long-Term Liabilities $4.369M $10.00K
Total Liabilities $6.375M $1.700M
YoY Change 274.96% -62.35%
SHAREHOLDERS EQUITY
Retained Earnings -$45.44M -$33.02M
YoY Change 37.61%
Common Stock $50.74M $611.00
YoY Change 8305004.26% 5.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.308M $11.69M
YoY Change
Total Liabilities & Shareholders Equity $11.68M $13.39M
YoY Change -12.76% -43.59%

Cashflow Statement

Concept 2015 Q3 2014 Q3
OPERATING ACTIVITIES
Net Income -$2.735M -$3.825M
YoY Change -28.49% 687.27%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.500M -$3.910M
YoY Change -36.06% 1348.15%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.360M 40.00K
YoY Change 8300.0% -99.83%
NET CHANGE
Cash From Operating Activities -2.500M -3.910M
Cash From Investing Activities
Cash From Financing Activities 3.360M 40.00K
Net Change In Cash 860.0K -3.870M
YoY Change -122.22% -117.06%
FREE CASH FLOW
Cash From Operating Activities -$2.500M -$3.910M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2006204
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1847993
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
611
CY2015Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3086
CY2014Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
126806
CY2014Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4196422
CY2014Q4 us-gaap Liabilities
Liabilities
6044415
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
45127202
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-35939149
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
9188664
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15233079
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6112091
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6112091
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2821382
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2420167
us-gaap Operating Expenses
OperatingExpenses
9267224
us-gaap Operating Expenses
OperatingExpenses
10235633
CY2015Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1207087
CY2015Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1837743
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
349915
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4405
CY2014Q3 us-gaap Interest Expense
InterestExpense
5906
us-gaap Interest Expense
InterestExpense
233208
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
294244
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8043365
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
843153
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8980199
us-gaap Interest Expense
InterestExpense
101240
us-gaap Operating Income Loss
OperatingIncomeLoss
-9267224
us-gaap Paid In Kind Interest
PaidInKindInterest
54076
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-7884
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
42875
us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
82685
CY2015Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4368749
CY2015Q3 us-gaap Liabilities
Liabilities
6374953
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
709
CY2015Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
50743478
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45436460
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
5307727
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11682680
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7085504
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7085504
CY2014Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3088373
us-gaap Operating Income Loss
OperatingIncomeLoss
-10235633
CY2015Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
470
CY2014Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1725
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
3121
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
8995
CY2015Q3 us-gaap Interest Expense
InterestExpense
78424
us-gaap Paid In Kind Interest
PaidInKindInterest
45521
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
3000000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. </p></div>
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
45000
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
71875
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1207087
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
854536
CY2014Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
49375
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
832036
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2007-01-29
CY2015Q3 evok Patient Enrollment Covenant
PatientEnrollmentCovenant
0.75
CY2014Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
108122
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
evok Legal Accounting And Filing Fees
LegalAccountingAndFilingFees
138000
CY2015Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
170000
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
41176
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2015Q3 us-gaap Share Based Compensation
ShareBasedCompensation
371675
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
303961
CY2015Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y2M19D

Files In Submission

Name View Source Status
0001564590-15-010586-index-headers.html Edgar Link pending
0001564590-15-010586-index.html Edgar Link pending
0001564590-15-010586.txt Edgar Link pending
0001564590-15-010586-xbrl.zip Edgar Link pending
evok-10q_20150930.htm Edgar Link pending
evok-20150930.xml Edgar Link completed
evok-20150930.xsd Edgar Link pending
evok-20150930_cal.xml Edgar Link unprocessable
evok-20150930_def.xml Edgar Link unprocessable
evok-20150930_lab.xml Edgar Link unprocessable
evok-20150930_pre.xml Edgar Link unprocessable
evok-ex311_8.htm Edgar Link pending
evok-ex312_9.htm Edgar Link pending
evok-ex321_6.htm Edgar Link pending
evok-ex322_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending